September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Naringenin inhibits corneal neovascularization by anti-inflammatory and anti-oxidant mechanisms
Author Affiliations & Notes
  • Ana Taba Oguido
    Ophyhalmology, Univeridade Estadual de Londrina, Londrina, Parana, Brazil
  • Antonio M B Casella
    Ophyhalmology, Univeridade Estadual de Londrina, Londrina, Parana, Brazil
  • Waldiceu Verri Junior
    Ophyhalmology, Univeridade Estadual de Londrina, Londrina, Parana, Brazil
  • Miriam Hohmann
    Ophyhalmology, Univeridade Estadual de Londrina, Londrina, Parana, Brazil
  • Felipe Ribeiro
    Ophyhalmology, Univeridade Estadual de Londrina, Londrina, Parana, Brazil
  • Footnotes
    Commercial Relationships   Ana Oguido, None; Antonio Casella, None; Waldiceu Verri Junior, None; Miriam Hohmann, None; Felipe Ribeiro, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3510. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Ana Taba Oguido, Antonio M B Casella, Waldiceu Verri Junior, Miriam Hohmann, Felipe Ribeiro; Naringenin inhibits corneal neovascularization by anti-inflammatory and anti-oxidant mechanisms. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3510.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Cornea neovascularization leads to a loss of its transparency and decline in vision. Inflammatory cells are involved in promoting angiogenesis by secreting pro angiogenic factors like vascular endothelial grown factors (VEGF) and other cytokines. Naringenin (4′, 5,7-trihydroxyflavanone) is a flavanone that has been considered an antioxidant, anti-inflammatory and anti angiogenic agent playing a role in the prevention of many diseases. We investigated the effect of eye drops containing narigenin in a corneal alkali injury model in mice.

Methods : Mice were divided into seven groups of five each. A control group without neovascular stimulus with and whithout naringerin eye drops, and an injured group (NaoH 1N), a treated group wich received isotonic solution (NaCL 0.9%) or progressive concentrations (0.01, 0.1, 1.0, and 10g/L) of narigenin eye drops (8µL). The treatment in the rigth eye of mice started 3 days before the injury procedure and continued for 7 days. The following were analyzed: neovasculariztion areas by biomicroscopic digital photography, myeloperoxidase (MPO) and n-acetyl-β-D glucosaminidase (NAG) activity, antioxidant acitivity (glutathione GSH, ferric reducing antioxidant power FRAP, ability to scavenge 2, 2'- Azinobis-(3-Ethylbenzothiazoline 6-Sulfonic acid ABTS) and IL-1β, IL-6 and IL-10 interleukines levels.

Results : Naringenin was more effective in the concentration of 10g/L as determined by MOP and NAG activity, on the third and seventh days after the injury procedure. Naringenin 10g/L reduced signicantly (p<0.01) the biomicroscopical neovascularization area. The total antioxidant capacity of naringenin (10g/L) eye drops was determined by reduced GSH, FRAP and ABTS assay, and they were prevented by 10g/L naringerin, 2,4 and 6 hours after injured. Morever, 10g/L naringenin solution inhibited the production of cytokines IL-1β and IL-6, significantly (p<0.05) and prevented the reduction of anti-inflammatory cytokine IL-10, measured 2, 4, 6 hours after injured by alcali. The results indicated that there were anti-inflammatory and antioxidant effects with the local eye drop use of narigenin.

Conclusions : We demonstrated the inhibitory effect of naringenin on corneal neovascularization of alkali-injured mice through anti-inflammatory and anti-oxidant mechanisms. Narigenin eye drops seem to be a promising adjunctive treatment for inflammatory neovascularization.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×